
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Cytosorbents Crp (CTSO)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CTSO (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $5
1 Year Target Price $5
1 | Strong Buy |
0 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -48.02% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 59.21M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 2 | Beta 1.2 | 52 Weeks Range 0.71 - 1.61 | Updated Date 08/29/2025 |
52 Weeks Range 0.71 - 1.61 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.04 | Actual -0.05 |
Profitability
Profit Margin -27.32% | Operating Margin (TTM) -37.59% |
Management Effectiveness
Return on Assets (TTM) -20.1% | Return on Equity (TTM) -69.67% |
Valuation
Trailing PE - | Forward PE 7.73 | Enterprise Value 75566668 | Price to Sales(TTM) 1.64 |
Enterprise Value 75566668 | Price to Sales(TTM) 1.64 | ||
Enterprise Value to Revenue 2.09 | Enterprise Value to EBITDA -1.92 | Shares Outstanding 62761800 | Shares Floating 54981852 |
Shares Outstanding 62761800 | Shares Floating 54981852 | ||
Percent Insiders 15.46 | Percent Institutions 26.66 |
Upturn AI SWOT
Cytosorbents Crp

Company Overview
History and Background
CytoSorbents Corporation was founded in 1997 and is a critical care immunotherapy company focused on developing and commercializing blood purification technologies to treat life-threatening illnesses. Its main product is CytoSorb, an extracorporeal cytokine adsorber.
Core Business Areas
- Critical Care: Develops and commercializes blood purification therapies for life-threatening conditions in the intensive care unit.
- Cardiac Surgery: Applies CytoSorb technology to improve outcomes in cardiac surgery by reducing inflammation.
- Transplantation: Investigates the use of CytoSorb in transplantation to reduce rejection risk.
Leadership and Structure
The company is led by Phillip Chan, MD, PhD (Chief Executive Officer), and has a structure typical of a publicly traded company with a board of directors and various departments.
Top Products and Market Share
Key Offerings
- CytoSorb: CytoSorb is the company's main product, designed to reduce excessive inflammation (cytokine storm) in critically ill patients. The product is approved in the European Union, but not yet approved in the United States. It's difficult to ascertain exact market share but it is significant within its applicable European market, especially for conditions like sepsis and during outbreaks of inflammatory illnesses. Competitors include companies developing similar blood purification technologies, and traditional therapies targeting inflammation, such as steroids. CytoSorbents also provides its HemoDefend and VetResQ product for targeted applications.
Market Dynamics
Industry Overview
The critical care and blood purification market is driven by the increasing prevalence of sepsis, acute respiratory distress syndrome (ARDS), and other inflammatory conditions. The market is competitive with various established and emerging technologies.
Positioning
CytoSorbents positions itself as a leader in cytokine adsorption, offering a unique solution for managing excessive inflammation in critical care settings. Its competitive advantage lies in the specific targeting of cytokines and its ability to be used in conjunction with other therapies.
Total Addressable Market (TAM)
The total addressable market for cytokine adsorption and blood purification therapies is estimated to be in the billions of dollars globally. CytoSorbents is positioned to capture a significant share of this market, particularly as it expands its regulatory approvals and clinical applications.
Upturn SWOT Analysis
Strengths
- Proprietary CytoSorb technology
- Approved in the European Union
- Expanding clinical applications
- Strong scientific evidence supporting efficacy
Weaknesses
- Not yet approved in the United States
- Reliance on single key product
- Financial losses and need for financing
- Dependence on reimbursement for adoption
Opportunities
- FDA approval in the United States
- Expansion into new clinical indications
- Strategic partnerships
- Growing awareness of cytokine storm
Threats
- Competition from established and emerging therapies
- Regulatory hurdles
- Reimbursement challenges
- Clinical trial failures
Competitors and Market Share
Key Competitors
- BAX
- NXTM
Competitive Landscape
CytoSorbents has a unique technology, but faces competition from larger, more established companies in the critical care and blood purification markets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by periods of rapid expansion followed by slower progress, influenced by regulatory approvals and clinical trial outcomes.
Future Projections: Future growth depends heavily on FDA approval and expansion into new clinical indications. Analyst estimates vary, but generally project continued revenue growth with a path towards profitability.
Recent Initiatives: Recent initiatives include pursuing FDA approval for CytoSorb, expanding clinical trials into new indications, and seeking strategic partnerships.
Summary
CytoSorbents is a company with promising technology in the cytokine adsorption space but is facing significant challenges in achieving profitability and securing FDA approval. Its strengths lie in its proprietary technology and expanding clinical applications, but weaknesses include its lack of US approval and reliance on a single key product. Future success hinges on navigating regulatory hurdles, securing reimbursement, and expanding its market reach.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Industry publications
- Company website
Disclaimers:
The data provided is for informational purposes only and should not be construed as investment advice. Market share data are estimates and may not be precise. Always conduct thorough due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cytosorbents Crp
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2013-11-07 | CEO & Director Dr. Phillip P. Chan M.D., Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 149 | Website https://www.cytosorbents.com |
Full time employees 149 | Website https://www.cytosorbents.com |
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; PuriFi, an advanced hemoperfusion pump for blood purification therapies; and ECOS-300CY, an ex vivo organ perfusion system to preserve or improve the health and quality of harvested solid organs to be transplanted. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.